Skip to main content

Advertisement

Table 1 Clinical and pathological data of the patients included in this study

From: A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97

(A) IPO Porto’s cohort
Clinicopathological features MNPT PCa
 Patients, n 14 100
 Median age, years (range) 65 (49–80) 65 (49–75)
 PSA (ng/mL), median (range) n.a. 8.45 (3.5–23)
 pT2 n.a. 60 (60%)
 pT3 n.a. 40 (40%)
 < 7 n.a. 36 (36%)
 = 7 n.a. 58 (58%)
 > 7 n.a. 6 (6%)
(B) TCGA’s cohort
Clinicopathological Features NAT PCa
 Patients, n 52 497
 Median age, years (range) 61 (43–72) 61 (41–78)
 pT2 29 (56%) 189 (38%)
 pT3 21 (40%) 292 (59%)
 pT4 2 (4%) 10 (2%)
 < 7 5 (10%) 45 (9%)
 = 7 40 (77%) 248 (50%)
 > 7 7 (13%) 204 (41%)
  1. MNPT morphologically normal prostate tissue, PCa prostate cancer, NAT normal adjacent tissue, n.a. not applicable
  2. (A) IPO Porto’s cohort (B) TCGA’s cohort